Form 4: Carter Todd Alfred reports sale transactions in VYGR

Rhea-AI Filing Summary

Carter Todd Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 3,525 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 153,193 shares.

Insider Trade Summary

Net Seller: 3,525 shares ($13,571)

Net Sell 1 txn

Insider Carter Todd Alfred

Role Chief Scientific Officer

Sold 3,525 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,525	$3.85	$14K

Holdings After Transaction: Common Stock — 153,193 shares (Direct)

Footnotes (1)

1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.71 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carter Todd Alfred

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S(1)		3,525(1)	D	$3.85(2)	153,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.71 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Todd Alfred Carter	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Voyager Therapeutics (VYGR) report on February 10, 2026?

Voyager Therapeutics reported a share sale by its Chief Scientific Officer, Todd Alfred Carter, on February 10, 2026. He sold 3,525 shares of common stock at a weighted average price of $3.85, as part of an automatic instruction tied to equity compensation.

Who is the Voyager Therapeutics (VYGR) insider involved in this Form 4 filing?

The insider is Todd Alfred Carter, who serves as Chief Scientific Officer of Voyager Therapeutics. He is listed as an officer but not a director or 10% owner, and this Form 4 details his sale of 3,525 shares and updated direct holdings.

How many Voyager Therapeutics (VYGR) shares did the insider sell and at what price?

Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics common stock at a weighted average price of $3.85 per share. The filing notes the shares were sold in multiple trades within a price range from $3.71 to $3.91, inclusive.

Was the Voyager Therapeutics (VYGR) insider trade discretionary or part of an automatic plan?

The sale was not discretionary. It was executed under a durable automatic sales instruction letter to effect a sell-to-cover election for tax withholding obligations arising from restricted stock units that vested on February 9, 2026.

How many Voyager Therapeutics (VYGR) shares does the insider own after the reported sale?

After the transaction, Todd Alfred Carter directly owned 153,193 shares of Voyager Therapeutics common stock. This updated holding reflects his position following the 3,525-share sale reported in the Form 4 filing.

What price range did the Voyager Therapeutics (VYGR) insider sale cover?

The reported weighted average price was $3.85, but the filing explains that individual trades occurred between $3.71 and $3.91 per share. The insider undertakes to provide detailed breakdowns of shares sold at each price upon request.